Cell Cycle Dysregulation in Mantle Cell Lymphoma: Genomics and Therapy.
CDK4
Cyclin D1
Ibrutinib
Mantle cell lymphoma
Palbociclib
Rb
p16(INK4a)
Journal
Hematology/oncology clinics of North America
ISSN: 1558-1977
Titre abrégé: Hematol Oncol Clin North Am
Pays: United States
ID NLM: 8709473
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
entrez:
31
8
2020
pubmed:
31
8
2020
medline:
2
6
2021
Statut:
ppublish
Résumé
Cell cycle dysregulation caused by aberrant cyclin D1 and CDK4 expression is a major determinant for proliferation of cancer cells in mantle cell lymphoma (MCL). Inhibition of CDK4/6 induces G1 arrest of MCL cells in patients, appearing to deepen and prolong the clinical response to partner agents. This article reviews aberrations of cell cycle genes in MCL cells and clinical trials of CDK4/6 inhibitors for MCL. Integrative longitudinal functional genomics is discussed as a strategy to discover genomic drivers for resistance in cancer cells and cancer-immune interactions that potentially contribute to the clinical response to palbociclib combination therapy in MCL.
Identifiants
pubmed: 32861279
pii: S0889-8588(20)30063-0
doi: 10.1016/j.hoc.2020.05.003
pmc: PMC7461610
mid: NIHMS1619101
pii:
doi:
Substances chimiques
CCND1 protein, human
0
Piperazines
0
Pyridines
0
Cyclin D1
136601-57-5
CDK4 protein, human
EC 2.7.11.22
CDK6 protein, human
EC 2.7.11.22
Cyclin-Dependent Kinase 4
EC 2.7.11.22
Cyclin-Dependent Kinase 6
EC 2.7.11.22
palbociclib
G9ZF61LE7G
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
809-823Subventions
Organisme : NCI NIH HHS
ID : P01 CA214274
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA188794
Pays : United States
Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of interest The authors have no conflicts of interest to declare.
Références
Cell Cycle. 2013 Jun 15;12(12):1892-900
pubmed: 23676220
Blood. 1999 Jun 15;93(12):4365-74
pubmed: 10361135
Proc Natl Acad Sci U S A. 2013 Nov 5;110(45):18250-5
pubmed: 24145436
Blood. 2016 Mar 24;127(12):1559-63
pubmed: 26764355
Blood. 2012 Mar 1;119(9):1963-71
pubmed: 22210878
Blood. 2019 Feb 28;133(9):940-951
pubmed: 30538135
Cancer Discov. 2018 Feb;8(2):216-233
pubmed: 29101163
Blood. 2012 Aug 2;120(5):1095-106
pubmed: 22718837
Mol Cancer Ther. 2004 Nov;3(11):1427-38
pubmed: 15542782
Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2773-8
pubmed: 10706620
Cancer Res. 1997 Oct 15;57(20):4608-14
pubmed: 9377576
Clin Cancer Res. 2013 Nov 15;19(22):6173-82
pubmed: 24045179
Blood. 2018 Jul 26;132(4):413-422
pubmed: 29769262
J Pathol. 1996 Jul;179(3):238-42
pubmed: 8774476
Haematologica. 2007 Apr;92(4):574-5
pubmed: 17488676
Sci Rep. 2017 Dec 21;7(1):18007
pubmed: 29269870
Blood. 2012 May 17;119(20):4597-607
pubmed: 22383795
Cancer Res. 2005 Mar 15;65(6):2199-206
pubmed: 15781632
N Engl J Med. 2013 Aug 8;369(6):507-16
pubmed: 23782157
Haematologica. 2000 Nov;85(11):1225-7
pubmed: 11064480
Leuk Lymphoma. 2017 Jun;58(6):1358-1365
pubmed: 27750483
Cancer Res. 2008 Jul 15;68(14):5519-23
pubmed: 18632601
Clin Cancer Res. 2009 Sep 15;15(18):5724-32
pubmed: 19723646
Breast Cancer Res. 2009;11(5):R77
pubmed: 19874578
Cancer Gene Ther. 2018 Jun;25(5-6):129-140
pubmed: 29755111
Cell. 2018 Nov 1;175(4):984-997.e24
pubmed: 30388455
Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2352-7
pubmed: 16461462
Blood. 2019 Mar 14;133(11):1201-1204
pubmed: 30692121
Cancer Cell. 2003 Feb;3(2):185-97
pubmed: 12620412
Blood. 2014 May 8;123(19):2988-96
pubmed: 24682267
Clin Cancer Res. 2016 Dec 1;22(23):5696-5705
pubmed: 27542767
Blood. 2007 Sep 15;110(6):2075-83
pubmed: 17537993
Int J Cancer. 2006 Jan 15;118(2):357-63
pubmed: 16080195
Blood. 2008 Feb 15;111(4):2385-7
pubmed: 18077791
Blood. 2007 Jun 15;109(12):5422-9
pubmed: 17332242
Blood. 2017 Oct 26;130(17):1903-1910
pubmed: 28819011
Blood. 2002 Jan 1;99(1):238-44
pubmed: 11756177
Leukemia. 1993 Sep;7(9):1437-40
pubmed: 8371593
Invest New Drugs. 2014 Oct;32(5):825-37
pubmed: 24919854
Cancer Res. 2010 Feb 15;70(4):1408-18
pubmed: 20124476
Blood. 1997 Jan 1;89(1):272-80
pubmed: 8978301
Cancer Res. 2006 Aug 1;66(15):7661-7
pubmed: 16885367
Blood. 2007 Jun 1;109(11):4599-606
pubmed: 17299095
Nature. 2017 Aug 24;548(7668):471-475
pubmed: 28813415
Int J Clin Exp Pathol. 2013;6(2):155-67
pubmed: 23330001
Oncogene. 1995 May 4;10(9):1833-40
pubmed: 7753558
Leuk Lymphoma. 2004 Oct;45(10):2143-7
pubmed: 15370262
Blood. 2011 Feb 17;117(7):2179-88
pubmed: 21163929
Leuk Lymphoma. 2019 Dec;60(12):2917-2921
pubmed: 31120355
Nat Med. 2019 Jan;25(1):119-129
pubmed: 30455436
Proc Natl Acad Sci U S A. 1991 Nov 1;88(21):9638-42
pubmed: 1682919
Br J Haematol. 2017 Nov;179(3):430-438
pubmed: 28832957
Cancer Discov. 2014 Sep;4(9):1022-35
pubmed: 25082755
Br J Haematol. 2018 Nov;183(4):578-587
pubmed: 30175400
Blood. 2015 Jul 30;126(5):604-11
pubmed: 26022239
Blood. 2013 Apr 18;121(16):3161-4
pubmed: 23407552
Nat Rev Cancer. 2019 Jun;19(6):326-338
pubmed: 31053804
Blood. 1994 Oct 15;84(8):2726-32
pubmed: 7919385
Cancer Cell. 2012 Oct 16;22(4):452-65
pubmed: 23079656
Blood. 2006 Sep 1;108(5):1744-50
pubmed: 16690963